sipuleucel

Patients in the 512-patient study who received Provenge, also known as sipuleucel-T, lived a median of 4.1 months longer than those who were given a placebo.

WN.com - Business News 2010

Provenge, also known as sipuleucel-T, lived a median of 4.1 months longer than those who were given a placebo.

WN.com - Business News 2010

PROVENGE® sipuleucel-T; fund new clinical trials for PROVENGE and other product candidates;

Dendreon Announces Offering of $500 Million Convertible Senior Notes Due 2016 - Yahoo! Finance 2011

PROVENGE® sipuleucel-T; fund new clinical trials for PROVENGE and other product candidates;

Dendreon Announces Pricing of $540 Million Convertible Senior Notes Due 2016 - Yahoo! Finance 2011

Patheon (TSX: PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry, announced today that it has signed a technology transfer agreement with Dendreon Corporation for commercial supply of proprietary density gradient solutions required during the PROVENGE (R) (sipuleucel-T) manufacturing process.

THE MEDICAL NEWS 2010

Mr. Brewer also currently serves as Chairman of the Board of Dendreon Corporation, which recently received FDA approval for PROVENGE® (sipuleucel-T), an autologous cellular immunotherapy for the treatment of prostate cancer.

The Earth Times Online Newspaper 2010

Dendreon's first autologous cellular immunotherapy product, PROVENGE® (sipuleucel-T), was approved by the FDA in April

The Earth Times Online Newspaper 2010

The piece, by staff writer Mark Roth, gets off to a bad start by reporting that, according to scientists, "we may be on the verge of being able to vaccinate people against cancer in the same way we do with infectious diseases … The first commercial cancer vaccine out of the gate is likely to be sipuleucel-T, a vaccine against prostate cancer being made by Dendreon Corp. of Seattle, Wash."

CJR 2010

/PRNewswire-FirstCall/-- Dendreon Corporation (Nasdaq: DNDN) today announced the presentation of safety data from the integrated analysis of four randomized PROVENGE® (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in prostate cancer at the 105th Annual

The Earth Times Online Newspaper 2010

Dendreon's first autologous cellular immunotherapy product, PROVENGE® (sipuleucel-T), was approved by the FDA in April 2010 for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.

RedOrbit News - Technology 2010